Article Text

Download PDFPDF
Reactive HIV testing and pre-exposure prophylaxis (PrEP) use in a London sexual health clinic
  1. Matthew Spencer,
  2. Sheel Patel,
  3. Gary Whitlock,
  4. Ilias Mavropoulos,
  5. Alan Mcowan,
  6. Victoria Tittle
  1. Department of GUM/HIV, Chelsea and Westminster Healthcare NHS Trust, London, UK
  1. Correspondence to Dr Matthew Spencer, Department of GUM/HIV, Chelsea and Westminster Healthcare NHS Trust, London, SW10 9NH, UK; matthew.spencer17{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

There are concerns pre-exposure prophylaxis (PrEP) may delay HIV seroconversion, but data are limited. We present a descriptive case note review of HIV testing outcomes from 56 Dean Street, a London sexual health clinic, from 1 January to 31 December 2021. Gender, age, sexual risk, PrEP history (using tenofovir disoproxil and …

View Full Text


  • Handling editor Anna Maria Geretti

  • Contributors MS and VT contributed to study design and data analysis. MS, VT, SP, GW, IM and AM all contributed to analysis of data. MS wrote the first draft of the letter. MS, VT, SP, GW and AM all reviewed the first draft. MS wrote subsequent drafts which were reviewed by VT.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.